|
|
|
|
|
|
|
The 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting |
|
|
|
|
| Phase 3, Randomized, Placebo Controlled Clinical Trial of CAN-2409+Prodrug in Combination with Standard of Care External Beam Radiation (EBRT) for Newly Diagnosed Localized Prostate Cancer |
| Glen Gejerman, MD, MBA |
| Glen Gejerman presented results from a phase III trial showing that CAN-2409 gene therapy plus EBRT significantly improved outcomes in localized, intermediate- or high-risk prostate cancer. Compared to placebo, CAN-2409 led to a 30% improvement in disease-free survival and a 38% reduction in recurrence or prostate cancer-related death, while also increasing rates of PSA nadir <0.2 ng/ml and 2-year pathological complete response. The therapy was safe, well-tolerated, and may represent the first new curative option in over 20 years for this patient population. |
|
|
|
|
|
| Stereotactic Radiotherapy in 3 Fractions for Localized Prostate Cancer |
| Giuseppe Sanguineti, MD |
| Giuseppe Sanguineti reported results from a prospective phase I/II trial of SBRT in 3 fractions for localized, low- to favorable intermediate-risk prostate cancer. At nearly 5 years of follow-up, treatment achieved excellent disease control with very low biochemical failure and no prostate cancer deaths, with a 5-year overall survival of 90%. The regimen was well-tolerated, showing limited GU and GI toxicity, supporting SBRT in 3 fractions as a safe and effective treatment option. |
|
|
|
|
|
| Two-Year Clinical Outcomes Following Ablative Radiotherapy for Unfavorable Prostate Tumors (ABRUPT)
|
| Stefano Arcangeli, MD
|
| Stefano Arcangeli presented 2-year outcomes from the ABRUPT trial, which tested single-dose radiotherapy plus ADT for organ-confined, unfavorable prostate cancer. The treatment was feasible, safe, and well-tolerated, with only low-grade GI/GU toxicities and no biochemical recurrences at 24 months. MRI showed strong radiologic responses, and while urinary symptoms worsened modestly, overall quality of life was largely maintained.
|
|
|
|
|
|
|
|
|
|
|
| Outcomes Following Radiation Therapy and Radical Prostatectomy in Patients with High-Risk Prostate Cancer in a Similar Access System |
| Abhishek Kumar, MD, MAS |
| Abhishek Kumar presented a study comparing outcomes of radiotherapy plus ADT versus radical prostatectomy in high-risk prostate cancer within a similar-access system. Radiotherapy was associated with a significantly lower risk of distant metastases, while overall survival was similar between surgery and radiotherapy for patients who were surgical candidates, but worse for non-surgical candidates receiving radiotherapy. |
|
|
|
|
|
| Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy followed by High-Dose Rate Brachytherapy Boost for High-Risk Adenocarcinoma of the Prostate (PCS VI)
|
| Tamim Niazi, MD
|
| Tamim Niazi presented the PCS VI trial, a phase III study comparing hypofractionated radiotherapy versus conventional pelvic radiotherapy followed by high-dose rate brachytherapy boost in high-risk prostate cancer. The trial found more frequent delayed Grade ≥1 and ≥2 gastrointestinal toxicities with hypofractionation, while genitourinary toxicities were similar between the two arms.
|
|
|
|
|
|
| Conventional vs. Hypofractionated, Radiotherapy for High-Risk Prostate Cancer: 10-Year Outcomes of the Randomized, Non-Inferiority, Phase 3 PCS5 Trial |
| Tamim Niazi, MD |
| Tamim Niazi presented the 10-year outcomes of the PCS5 trial, a phase III study comparing conventional versus hypofractionated radiotherapy for high-risk prostate cancer with long-term ADT. The trial found no significant differences in overall, prostate cancer-specific, biochemical failure-free, or metastasis-free survival between the two arms, confirming that hypofractionation is non-inferior. |
|
|
|
|
|
| 5-Year Results of a Prospective, Non-Randomized Controlled Study: Comparison of the Efficacy and Safety of ADT + Docetaxel vs. ADT + Novel Hormone Therapy in High Gleason Score Non-Metastatic Prostate Cancer Patients Receiving Radiotherapy |
| Ming-Wei Ma, MD, PhD |
| Ming-Wei Ma presented 5-year results from a prospective, non-randomized study comparing ADT + docetaxel versus ADT + novel hormonal therapy in non-metastatic, high Gleason score prostate cancer patients receiving radiotherapy. The study found that docetaxel intensification significantly improved 5-year failure-free survival and showed trends toward better biochemical relapse-free and metastasis-free survival, though with higher rates of manageable hematologic and GU/GI toxicities. |
|
|
|
|
|
|
|
|
|
|
